Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments
Asia-Pacific Journal of Ophthalmology · 2025
DOI: 10.1016/j.apjo.2025.100176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2025. Verfasst von Voraporn Chaikitmongkol und 10 weiteren Autor:innen. Beteiligte Einrichtung: Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Polyps, Choroid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Faculty of Medicine, Chiang Mai University, Johns Hopkins University, Johns Hopkins University School of Medicine.
Abstract (Originalsprache)
PURPOSE: Polypoidal choroidal vasculopathy (PCV) may have frequent recurrences after fluid resolution, but time to recurrence is unclear. This study explored time to first polypoidal recurrence after 1-year fixed-dosing aflibercept treatments. DESIGN: Retrospective cohort study. METHODS: Treatment-naïve PCV eyes treated between April 2015 to May 2019 were identified and included with criteria including: (1) received fixed-dosing 2 mg aflibercept in the first year, (2) became "inactive" (absence of both intraretinal and subretinal fluid on OCT) at post-treatment year-1 (PTY1) and managed as needed (PRN) thereafter, (3) FU ≥ 12 months after PTY1. Fundus photography, indocyanine green angiography (ICGA), and OCT graded to identify timing and risk factors for recurrence (defined as fluid on OCT). RESULTS: Of 37 study eyes [37 patients; median age was 64 years (IQR 59-69); median aflibercept injection number was 8 (IQR 8-8); median FU 38 months (IQR, 30-50 months)]; 18 eyes (49 %) had recurrence during FU. Fourteen (78 %) of 18 had recurrence within 12 months after PTY1 visit. Risk factors for recurrence included: incomplete polypoidal regression on post-treatment ICGA [P = .004, Hazard ratio (HR) = 4.4, 95 % confidence interval (CI) 1.6-11.9] and PED with internal heterogeneous reflectivity on post-treatment OCT (P = .04, HR = 2.7, 95 % CI 1.1-6.9). CONCLUSIONS: Nearly half of inactive PCV eyes following 1-year fixed-dosing aflibercept treatments had recurrent polypoidal lesions. Eyes with high-risk features for recurrence, some of which can be detected with OCT without the need for ICGA, may warrant close monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Department of Ophthalmology, Nakornping Hospital, Chiang Mai, Thailand.
- Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Department of Ophthalmology, Lanna Hospital, Chiang Mai, Thailand.
- Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: nmboffice@jhmi.edu.
Förderung
- Faculty of Medicine, Chiang Mai University
- Johns Hopkins University
- Johns Hopkins University School of Medicine
Zitieren
APA
Chaikitmongkol, V., Tadadoltip, W., Patikulsila, D., Srisomboon, T., Narongchai, C., Choovuthayakorn, J., Watanachai, N., Kunavisarut, P., Sangkaew, A., Upaphong, P., & Bressler, N. M. (2025). Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments. Asia-Pacific Journal of Ophthalmology. https://doi.org/10.1016/j.apjo.2025.100176
Vancouver
Chaikitmongkol V, Tadadoltip W, Patikulsila D, Srisomboon T, Narongchai C, Choovuthayakorn J, et al. Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments. Asia-Pacific Journal of Ophthalmology. 2025. doi:10.1016/j.apjo.2025.100176
BibTeX
@article{Chaikitmongkol2025,
author = {Chaikitmongkol, Voraporn and Tadadoltip, Wantip and Patikulsila, Direk and Srisomboon, Titipol and Narongchai, Chanusnun and Choovuthayakorn, Janejit and Watanachai, Nawat and Kunavisarut, Paradee and Sangkaew, Apisara and Upaphong, Phit and Bressler, Neil M},
title = {Recurrent polypoidal lesions after achieving inactive polypoidal choroidal vasculopathy following 1-year fixed-dosing aflibercept treatments},
journal = {Asia-Pacific Journal of Ophthalmology},
year = {2025},
doi = {10.1016/j.apjo.2025.100176}
}
EUVIMED